Industry News

12 July 2025

Wockhardt to exit U.S. operations to prioritize innovation

Indian pharmaceutical company Wockhardt has announced a significant strategic shift in its U.S. operations, marking a new chapter focused on innovation-led growth and portfolio rationalization. The company is phasing out its conventional U.S. generics business to channel efforts into high-value specialty products and innovative therapies.

11 July 2025

Glenmark and AbbVie sign USD 700 million drug licensing agreement

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGIs lead investigational asset, ISB 2001, developed using IGIs proprietary BEAT protein platform, for oncology and autoimmune diseases

11 July 2025

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

Ascentage Pharma a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval

11 July 2025

Milestone Pharmaceuticals announces FDA acceptance of the Company’s Response to the CRL for CARDAMYST (etripamil) Nasal Spray

Milestone Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025.

9 July 2025

Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab

Lupin Limited and Zentiva Group , a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialization of Lupins biosimilar Certolizumab Pegol, across multiple markets globally.

7 July 2025

Biocon Biologics secures UK MHRA approval for Denosumab biosimilars Vevzuo® and Evfraxy®

Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has announced that the UKs Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for its Denosumab biosimilars, Vevzuo® and Evfraxy

5 July 2025

Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the United States

Global pharma major Lupin Limited announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States.

3 July 2025

Novartis shares phase III GCAptAIN trial results: Cosentyx falls short of primary goal in treating Giant Cell Arteritis

Novartis has announced the top-line results of its Phase III GCAptAIN study, evaluating Cosentyx (secukinumab) in patients with giant cell arteritis (GCA) a serious inflammatory condition that primarily affects adults over the age of 50.

2 July 2025

European Commission Approves Vertex’s Next-Generation Cystic Fibrosis Therapy, ALYFTREK®

Vertex Pharmaceuticals has announced that the European Commission has approved its newest cystic fibrosis treatment, ALYFTREK a once-daily, triple-combination therapy made up of deutivacaftor, tezacaftor, and vanzacaftor.

1 July 2025

Biological E. and Recbio partner to bring HPV9 Vaccine to India and global markets

In a significant development for global health, Hyderabad-based Biological E. Limited has joined hands with Chinese biopharmaceutical firm Jiangsu Recbio Technology Company Limited to produce and distribute the 9-valent Human Papillomavirus (HPV9) vaccine, REC603.

Search

Wockhardt to exit U.S. operations to prioritize innovation

RECOMMENDED POSTS

Subscribe with us

Jobs by Category